Quantum precision reached in modeling molten salt behavior
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
Processes like manufacturing aircraft parts, analyzing data from doctors’ notes and identifying national security threats may seem unrelated, but at the U.S. Department of Energy’s Oak Ridge National Laboratory, artificial intelligence is improving all of these tasks.
Artificial intelligence (AI) techniques have the potential to support medical decision-making, from diagnosing diseases to prescribing treatments. But to prioritize patient safety, researchers and practitioners must first ensure such methods are accurate.
Oak Ridge National Laboratory is using artificial intelligence to analyze data from published medical studies associated with bullying to reveal the potential of broader impacts, such as mental illness or disease.
OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.